The Swiss Competition Commission announced on Thursday that it has terminated the investigation into Novartis AG pharmaceutical with no consequences.
It was reported by China Finance that the Swiss Competition Commission (COMCO) announced on Thursday that it has terminated the investigation into Novartis AG (NVS.US) with no consequences. The purpose of the commission was to determine whether Novartis was attempting to illegally protect one of its skin disease drugs by initiating various patent infringement lawsuits. The investigation results indicated that Novartis' actions were common practices in the field of patent law, and there was no evidence of illegal competition restrictions as mentioned above. Therefore, the Swiss Competition Commission closed the investigation.
In a statement, the commission stated that COMCO initiated the investigation in September 2022 to determine if the pharmaceutical giant planned to illegally protect its pharmaceuticals through various patent infringement lawsuits. The company stated in the declaration: "The investigation shows that Novartis' actions have ultimately become common practice in the field of patent law, and furthermore, the investigation did not confirm any signs of illegal competition restrictions as mentioned above."
